This week the Food and Drug Administration (FDA) announced that it would be hosting a public meeting in the month of November to explain the effects of CBD and marijuana compounds on sex and gender differences.
According to a notice, the FDA’s Office of Women’s Health announced the event.
“Researchers, educators, clinicians, and patients may benefit from attending this multidisciplinary scientific conference on CBD and other cannabinoids,” the FDA said. “Presentations will address patient and healthcare provider perspectives on CBD and other cannabinoid use, sex differences in the effects of CBD and other cannabinoids, use of CBD and other cannabinoids in pregnancy, and government agency perspectives on CBD research and evaluation.”
“FDA recognizes the significant public interest in cannabis and cannabis-derived compounds, particularly CBD. However, there are many unanswered questions about the science, safety, and quality of products containing CBD. The Agency is working on answering these questions through ongoing efforts including feedback from a FDA hearing and information and data gathering through a public docket.”
The meeting will take place on November 19 and those who want to attend must register online by November 16th.
“Conditions for which CBD is often marketed, such as chronic pain, anxiety, depression, and sleep disturbances, are more prevalent in women than men,” FDA said in its Federal Register notice. “Therefore, consideration of issues pertaining to the safety of CBD products may be particularly important to address in women.”
The agency said that each session at the November event will include a question and answer component.